eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
1/2012
vol. 7
 
Share:
Send email
Share:
abstract:
Original paper

The importance of IL28B polymorphism in response to pegylated interferon α and ribavirin in chronic hepatitis caused by HCV genotype 1b

Tomasz Mach
,
Andrzej Cieśla
,
Marek Sanak
,
Mikołaj Głowacki
,
Wioleta Warunek
,
Danuta Owczarek
,
Irena Ciećko-Michalska

Przegląd Gastroenterologiczny 2012; 7 (1): 38–42
DOI: https://doi.org/10.5114/pg.2012.27221
Online publish date: 2012/02/29
View full text Get citation
 
PlumX metrics:
Introduction : Treatment of chronic hepatitis C (CH-C) with peginterferon α (Peg-IFN) and ribavirin leads to a sustained virological response (SVR) in 50% of patients and depends on HCV and host factors. Polymorphism of the IL28B gene is associated with eradication of HCV and SVR.

Aim: The objective of this study was to examine patients from the region of southern Poland and determine whether CH-C therapy depends on the genetic variants of IL28B and whether this polymorphism may predict SVR.

Material and methods: One hundred forty-two patients with CH-C and the genotype 1b HCV were treated with Peg-IFN and ribavirin for 48 weeks. IL28B rs12979860 polymorphisms (C/T) were tested by PCR-RFLP. The HCV-RNA and alanine aminotransferase (ALT) levels were measured before treatment and after 12, 48 and 72 weeks.

Results : Viral load before and after 12 weeks of therapy was higher in the genotypes T/C and T/T than in C/C. 71.1% of patients with the genotype C/C achieved SVR vs. 41.4% with the genotype T/C and 23.5% with T/T. Patients with the genotype C/C responded better to treatment as compared to subjects with the genotypes T/C and T/T, and achieved better early response (12 weeks), at the end of treatment (48 weeks) and SVR. Alanine aminotransferase activity was similar among the groups. Tolerance of therapy was similar and independent of the genotypes.

Conclusions: The study confirmed the dependence of response to standard treatment of CH-C caused by the genotype 1b HCV on the patient's genetic predisposition. In contrast to some other reports, poor prognosis was observed in T/T homozygotes of IL28B .
keywords:

chronic hepatitis, HCV, IL28B , treatment
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.